Rigel Pharmaceuticals, Inc. (RIGL) Analysts See $-0.16 EPS

October 13, 2018 - By Hugh Holland

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) LogoInvestors sentiment increased to 2.92 in 2018 Q2. Its up 1.69, from 1.23 in 2018Q1. It improved, as 10 investors sold Rigel Pharmaceuticals, Inc. shares while 16 reduced holdings. 29 funds opened positions while 47 raised stakes. 141.97 million shares or 12.15% more from 126.59 million shares in 2018Q1 were reported.
State Street Corporation has 8.00M shares. 81,934 were accumulated by State Board Of Administration Of Florida Retirement. Wells Fargo & Mn holds 0% or 86,843 shares. Price T Rowe Assocs Inc Md holds 3.54M shares. Geode Capital Mgmt Limited Liability holds 1.65 million shares. Creative Planning owns 10,000 shares for 0% of their portfolio. Art Advsr Ltd Limited Liability Company reported 0.05% stake. The New York-based Bancorporation Of Mellon has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Principal Financial Grp holds 0% or 45,847 shares. Barclays Public Ltd has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Swiss Bank stated it has 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 12,653 shares. Schwab Charles Investment Incorporated holds 0% or 355,800 shares. Moreover, D E Shaw And Inc has 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Bank & Trust Of Montreal Can reported 49,230 shares.

Since April 20, 2018, it had 3 insider purchases, and 4 insider sales for $280,029 activity. Shares for $300,002 were bought by RODRIGUEZ RAUL R. $282,320 worth of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares were bought by Mayer Eldon C. III.

Analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $-0.16 EPS on November, 6.They anticipate $0.02 EPS change or 14.29 % from last quarter’s $-0.14 EPS. After having $-0.16 EPS previously, Rigel Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. It closed at $3.1 lastly. It is down 24.40% since October 14, 2017 and is uptrending. It has outperformed by 8.78% the S&P500.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Among 4 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals had 8 analyst reports since April 18, 2018 according to SRatingsIntel. BMO Capital Markets maintained it with “Outperform” rating and $10 target in Wednesday, May 2 report. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, April 18. As per Wednesday, April 18, the company rating was maintained by BMO Capital Markets. Cantor Fitzgerald maintained the shares of RIGL in report on Tuesday, April 17 with “Buy” rating. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 1. The firm earned “Buy” rating on Wednesday, May 2 by H.C. Wainwright. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Tuesday, June 26 with “Buy” rating.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $515.97 million. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

More recent Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on September 28, 2018. Also Seekingalpha.com published the news titled: “Rigel Pharmaceuticals (RIGL) Investor Presentation – Slideshow” on October 05, 2018. Seekingalpha.com‘s news article titled: “EMA accepts Rigel’s marketing application for fostamatinib for immune thrombocytopenia; shares up 2% premarket” with publication date: October 11, 2018 was also an interesting one.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>